Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS0159 and Semaglutide in MASH with Obesity and T2DM
NCT06492330Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jul 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of linafexor in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Shanghai Jiao Tong University School of Medicine. Started Jul 2024; status: completed.
02
Drugs
linafexor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06492330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492330.